Angiotensin converting enzyme inhibitors (ACEi) and receptor blockers (ARB) were shown to reduce all-cause mortality and risk of sudden cardiac death (SCD) in patients with acute myocardial infarction (AMI) and heart failure (HF) with reduced left ventricular ejection fraction (i.e., LVEF ≤ 40%) when prescribed for primary prevention of SCD [1,2,3,4]. Here, ACE is linked to heart failure.